Allogene Therapeutics, Inc. (ALLO)
Company Info
| ISIN | US0197701065 |
|---|---|
| CUSIP | 019770106 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $586.75M |
|---|---|
| EPS | -$2.09 |
| PE Ratio | 0.00 |
| Revenue (TTM) | $95.00K |
| Gross Profit (TTM) | $243.00K |
| EBITDA (TTM) | -$300.29M |
| Year Range | $2.23 - $6.89 |
| Target Price | $9.69 |
| Short % | 26.60% |
| Short Ratio | 11.76 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Allogene Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Allogene Therapeutics, Inc. had a return of -5.30% year-to-date (YTD) and -45.71% in the last 12 months.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | -5.30% | 6.33% |
| 1 month | -29.14% | -2.81% |
| 6 months | 14.29% | 21.13% |
| 1 year | -45.71% | 24.56% |
| 5 years (annualized) | -36.74% | 11.55% |
| 10 years (annualized) | N/A | 10.55% |
Monthly Returns Heatmap
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 9.66% | 39.49% | -8.96% | |||||||||
| 2023 | -18.51% | -11.04% | -16.67% | 36.60% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
Allogene Therapeutics, Inc.(ALLO)
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Allogene Therapeutics, Inc. (ALLO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Allogene Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Allogene Therapeutics, Inc. was 95.78%, occurring on Nov 29, 2023. The portfolio has not yet recovered.
The current Allogene Therapeutics, Inc. drawdown is 94.37%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -95.78% | May 26, 2020 | 886 | Nov 29, 2023 | — | — | — |
| -45.29% | Nov 7, 2018 | 341 | Mar 18, 2020 | 37 | May 11, 2020 | 378 |
| -16.54% | Oct 16, 2018 | 7 | Oct 24, 2018 | 7 | Nov 2, 2018 | 14 |
| -7.25% | May 12, 2020 | 2 | May 13, 2020 | 1 | May 14, 2020 | 3 |
| -0.39% | May 19, 2020 | 1 | May 19, 2020 | 1 | May 20, 2020 | 2 |
Volatility
Volatility Chart
The current Allogene Therapeutics, Inc. volatility is 16.06%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | 0.00 |
Cost Of Revenue | 0.00 |
Gross Profit | 0.00 |
| Operating Expenses | |
Selling, General & Admin Expenses | 0.00 |
R&D Expenses | 0.00 |
Total Operating Expenses | 0.00 |
| Income | |
Income Before Tax | 0.00 |
Operating Income | 0.00 |
EBIT | 0.00 |
Earnings From Continuing Operations | 0.00 |
Net Income | 0.00 |
Income Tax Expense | 0.00 |
Interest Expense | 0.00 |
Other Non-Operating Income (Expenses) | 0.00 |
Extraordinary Items | 0.00 |
Discontinued Operations | 0.00 |
Effect Of Accounting Charges | 0.00 |
Non Recurring | 0.00 |
Minority Interest | 0.00 |
Other Items | 0.00 |